冠心病心绞痛患者中医证候与相关血清蛋白表达的研究

被引:0
作者
宋庆桥
机构
[1] 中国中医科学院
关键词
冠心病心绞痛; 中医; 证候; 多因子降维; 液态蛋白芯片技术;
D O I
暂无
年度学位
2010
学位类型
博士
导师
摘要
背景:随着社会经济的发展和人们生活方式的改变,冠心病心绞痛的发病率逐年提高,已经成为影响人类寿命和生存质量的主要疾病之一。对其进行研究具有重要的社会意义和卫生经济学意义。中医药治疗慢性稳定性心绞痛具有独特的价值,然其证候规律、证候的临床特征、产生机理及预后价值尚缺乏统一认识,有待于进一步研究,为冠心病、心绞痛中医证候的临床诊断、辨证论治提供依据,以利于充分发挥中医药优势。 目的:探讨冠心病心绞痛中医常见证候临床表现特征与相关血清蛋白质表达的关系。 方法: 1.冠心病稳定性心绞痛患者临床中医证候学研究:分析经冠状动脉造影证实的冠心病稳定性心绞痛患者临床证候学特点,包括冠心病心绞痛患者证候要素及常见证候分布特点,观察常见证候及证候要素之间危险因素、冠脉病变程度的差异;采用MDR方法初步构建相关模型,计算冠心病心绞痛患者临床表现与证候要素、常见证候之间的关系。 2.冠心病稳定性心绞痛患者相关蛋白质表达与证候关系研究:采用液相蛋白芯片分析方法同步检测冠心病心绞痛患者血清sE-Selectin, sVCAM-1, sICAM-1, MMP-9, MPO, tPAI-1含量,统计证候要素、常见证候之间上述蛋白质表达差异,研究证候要素、常见证候与血清蛋白质表达的关系。 结果: 1.冠心病稳定性心绞痛患者临床经常出现的证候要素分布为痰147例次、瘀145例次、气虚115例次、阴虚73例次、气滞14例次、阳虚24例次、热22例次、寒4例次;常见证候有气虚血瘀证85例次、痰瘀互结证92例次、阴虚痰阻证56例次、气虚痰阻证86例次、气滞血瘀证14例次、阴虚血瘀证40例次、阳虚痰阻证15、气虚血瘀痰阻证56例次、气阴两虚痰阻证42例次、气阴两虚痰瘀证21例次。不同证候之间,患者冠心病危险因素、冠脉病变程度差异均无显著的统计学意义。 2.冠心病心绞痛患者证候要素、常见证候的临床表现特征:寒(头晕、心悸、情志抑郁和脉络形态),准确性,0.884,敏感性,1.000,特异性,0.881,预测准确性, 0.143;气虚,(面色淡白、心痛如刺、唇舌紫暗、腰酸),准确性,0.718,敏感性,0.722,特异性,0.714,预测准确性,0.762;气滞,(善太息、心痛如刺、下肢浮肿、舌质斑点或瘀斑)准确性,0.786,敏感性,1,特异性,0.771,预测准确性,0.241;热,(心悸、唇色紫暗、舌下脉络颜色、脘腹痞闷),准确性,0.704,敏感性,0.909,特异性,0.679,预测准确性,0.253;痰,(脘腹痞闷、心悸、舌下脉络颜色、唇舌紫暗),准确性,0.762,敏感性,0.748,特异性,0.797,预测准确性,0.902;阳虚,(脘腹痞闷、舌下脉络颜色、唇舌紫暗、心悸)准确性,0.704,敏感性,0.875,特异性,0.681,预测准确性,0.266;阴虚,(脘腹痞闷、心悸、舌下脉络颜色、唇舌紫暗),准确性,0.728,敏感性,0.795,特异性,0.692,预测准确性,0.586;瘀,(脘腹痞闷、心悸、舌下脉络颜色、唇舌紫暗);准确性,0.7476,敏感性,0.731,特异性,0.7869,预测准确性,0.8908;气虚血瘀,(便秘、心悸、舌下脉络形态、体胖多痰)准确性,0.8204,敏感性,0.8947,特异性,0.8128,预测准确性,0.3269;痰瘀互结,(便秘、心悸、舌下脉络形态、体胖多痰),准确性,0.7718,敏感性,1,特异性,0.759,预测准确性,0.1897;阴虚痰阻,(心悸、体胖多痰、便秘、舌下脉络形态)准确性,0.825,敏感性,1.000,特异性,0.818,预测准确性,0.182;气虚痰阻,(心胸胀痛、五心烦热、善太息、情志抑郁),准确性,0.898,敏感性,1.000,特异性,0.895,预测准确性,0.250;气滞血瘀,神疲、心胸胀痛、舌下脉络形态、细脉),准确性,0.854,敏感性,1.000,特异性,0.849,预测准确性,0.189;阴虚血瘀,(心悸、体胖多痰、便秘、脉络),准确性,0.854,敏感性,1.000,特异性,0.849,预测准确性,0.189;阳虚痰阻,(心悸、体胖多痰、便秘、舌下脉络形态),准确性,0.864,敏感性,1.000,特异性,0.859,预测准确性,0.200;气虚血瘀痰阻,(脘腹痞闷、心悸、舌下脉络颜色、唇舌紫暗),准确性,0.7476,敏感性,0.8529,特异性,0.7267,预测准确性,0.3816;气阴两虚痰阻,(心悸、体胖多痰、舌下脉络形态、便秘)准确性,0.830,敏感性,1.000,特异性,0.816,预测准确性,0.314;气阴两虚痰瘀证,(体胖多痰、心胸胀痛、舌苔色白和面色淡白),准确性,0.811,敏感性,0.950,特异性,0.796,预测准确性,0.333。 3.冠心病稳定性心绞痛患者血清sVCAM-1(ln), sICAM-1(ln), MMP-9(ln), MPO(ln), tPAI-1蛋白表达均显著高于健康对照组,p值均<0.01,sE-selectin (In)在稳定性心绞痛患者和健康对照组的表达差异没有显著的统计学意义(p=0.067)。 4.相关血清蛋白在冠心病心绞痛各证候要素中表达:tPAI-1在痰、瘀、气虚、阴虚、热证候要素中升高;sVCAM-1在痰、瘀、气虚、气滞、阴虚、热证候要素中升高;sICAM在痰、瘀、气虚、气滞、阴虚、热证候要素中升高;MMP-9在痰、瘀、气虚、气滞、阴虚、热证候要素中升高,sE-Selectin在痰、瘀、气虚、阴虚证候要素中升高;MPO在痰、瘀、气虚、气滞、阳虚、热证候要素中升高。 5.相关血清蛋白在冠心病心绞痛常见证候中表达:tPAI-1在气虚血瘀证、痰瘀互结证、阴虚痰阻证、气虚痰阻证、阴虚血瘀证、气虚血瘀痰阻证、气阴两虚痰阻证、气阴虚两虚痰瘀证中表达升高较显著(p<0.01);sVCAM-1在气虚血瘀证、痰瘀互结证、阴虚痰阻证、气虚痰阻证、阴虚血瘀证、气虚血瘀痰阻证、气阴两虚痰阻证、气阴虚两虚痰瘀证中表达升高较显著(p<0.01);sICAM在气虚血瘀证、痰瘀互结证、气虚痰阻证、气滞血瘀证、气虚血瘀痰阻证、气阴两虚痰阻证、气阴两虚痰瘀证表达较健康对照组及阳虚痰阻证显著升高(p<0.01);MMP-9在气虚血瘀证、痰瘀互结证、气虚痰阻证、气滞血瘀证、气虚血瘀痰阻证、气阴两虚痰阻证、气阴两虚痰瘀证表达升高显著(p<0.01或0.05);sE-Selectin在气虚血瘀证、痰瘀互结证、气虚痰阻证、阴虚痰阻证、阴虚血瘀证、气虚血瘀痰阻证、气阴两虚痰阻证、气阴两虚痰瘀证显著高于健康对照组和阳虚痰阻证(p<0.01);MPO在气虚血瘀证、痰瘀互结证、气虚痰阻证、阴虚痰阻证、阴虚血瘀证、气虚血瘀痰阻证、气阴两虚痰阻证、气阴两虚痰瘀证表达均显著升高(p<0.01)。 结论: 1.冠心病稳定性心绞痛患者临床常见证候要素痰、瘀、气虚、阴虚、气滞、阳虚、热、寒;常见证候气虚血瘀证、痰瘀互结证、阴虚痰阻证、气虚痰阻证、气滞血瘀证、阴虚血瘀证、阳虚痰阻证、气虚血瘀痰阻证、气阴两虚痰阻证、气阴两虚痰瘀证。 2.冠心病心绞痛证候要素临床表现特征:寒(头晕、心悸、情志抑郁和脉络形态),气虚(面色淡白、心痛如刺、唇舌紫暗、腰酸),气滞(善太息、心痛如刺、下肢浮肿、舌质斑点或瘀斑),热(心悸、唇色紫暗、舌下脉络颜色、脘腹痞闷),痰(脘腹痞闷、心悸、舌下脉络颜色、唇舌紫暗),阳虚(脘腹痞闷、舌下脉络颜色、唇舌紫暗、心悸),阴虚(脘腹痞闷、心悸、舌下脉络颜色、唇舌紫暗),血瘀(脘腹痞闷、心悸、舌下脉络颜色、唇舌紫暗)。 3.冠心病心绞痛常见证候临床表现特征:气虚血瘀(便秘、心悸、舌下脉络形态、体胖多痰),痰瘀互结(便秘、心悸、舌下脉络形态、体胖多痰),阴虚痰阻(心悸、体胖多痰、便秘、舌下脉络形态),气虚痰阻(心胸胀痛、五心烦热、善太息、情志抑郁),气滞血瘀(神疲、心胸胀痛、舌下脉络形态、细脉),阴虚血瘀(心悸、体胖多痰、便秘、脉络),阳虚痰阻(心悸、体胖多痰、便秘、舌下脉络形态),气虚血瘀痰阻(脘腹痞闷、心悸、舌下脉络颜色、唇舌紫暗),气阴两虚痰阻(心悸、体胖多痰、舌下脉络形态、便秘),气阴两虚痰瘀证(体胖多痰、心胸胀痛、舌苔色白和面色淡白)。 4.冠心病稳定性心绞痛患者血清sVCAM-1(ln), sICAM-1(ln), MMP-9(ln), MPO(ln), tPAI-1蛋白均显著高于健康对照组。 5.冠心病稳定性心绞痛证候要素中,痰、瘀、气虚、阴虚、热证素的血清tPAI-1、sVCAM-1、sICAM-1、sE-selectin、MMP-9、MPO蛋白表达升高;气滞证素血清sVCAM-1、MMP-9、MPO蛋白表达升高;阳虚证素MPO蛋白表达升高; 6.冠心病稳定性心绞痛常见证候中气虚血瘀、痰瘀互结、阴虚痰阻、气虚痰阻、阴虚血瘀证候的血清tPAI-1、sVCAM-1、sICAM-1、sE-selectin、MMP-9、MPO蛋白表达升高;气滞血瘀证候血清sVCAM-1、sICAM-1、MMP-9、MPO蛋白表达升高;气虚血瘀痰阻证、气阴两虚痰阻证、气阴两虚痰瘀证证候tPAI-1、sVCAM-1、sICAM-1、sE-selectin、MMP-9、MPO蛋白表达升高。
引用
收藏
页数:105
共 93 条
[1]
冠心病中医辨证分型与血清脂联素、抵抗素及血脂水平的相关性研究 [D]. 
张蓓蓓 .
南京中医药大学,
2006
[2]
Relation of Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio in Peripheral Circulating CD14+Monocytes to Progression of Coronary Artery Disease [J].
Brunner, Stefan ;
Kim, Jong-Oh ;
Methe, Heiko .
AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (04) :429-434
[3]
Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease [J].
Konstantino, Yuval ;
Nguyen, Tu T. ;
Wolk, Robert ;
Aiello, Robert J. ;
Terra, Steven G. ;
Fryburg, David A. .
BIOMARKERS, 2009, 14 (02) :118-129
[4]
Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome [J].
Cheng, Min ;
Hashmi, Satwat ;
Mao, Xiaobo ;
Zeng, Qiu Tang .
CANADIAN JOURNAL OF CARDIOLOGY, 2008, 24 (05) :385-390
[5]
Release of protein as well as activity of MMP-9 from unstable atherosclerotic plaques during percutaneous coronary intervention [J].
Robertson, L. ;
Grip, L. ;
Hulten, L. Mattsson ;
Hulthe, J. ;
Wiklund, O. .
JOURNAL OF INTERNAL MEDICINE, 2007, 262 (06) :659-667
[6]
Comparison between metalloproteinases-2 and-9 in healthy subjects, diabetics, and subjects with acute coronary syndrome [J].
Derosa, Giuseppe ;
D'Angelo, Angela ;
Scalise, Filippo ;
Avanzini, Maria A. ;
Tinelli, Carmine ;
Peros, Emmanouil ;
Fogari, Elena ;
Cicero, Arrigo F. G. .
HEART AND VESSELS, 2007, 22 (06) :361-370
[7]
Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease [J].
Otsuka, Fumiyuki ;
Sugiyama, Seigo ;
Kojima, Sunao ;
Maruyoshi, Hidetomo ;
Funahashi, Tohru ;
Matsui, Kunihiko ;
Sakamoto, Tomohiro ;
Yoshimura, Michihiro ;
Kimura, Kazuo ;
Umemura, Satoshi ;
Ogawa, Hisao .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (06) :1155-1162
[8]
Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions - A study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms [J].
Sluijter, JPG ;
Pulskens, WPC ;
Schoneveld, AH ;
Velema, E ;
Strijder, CF ;
Moll, F ;
de Vries, JP ;
Verheijen, J ;
Hanemaaijer, R ;
de Kleijn, DPV ;
Pasterkamp, G .
STROKE, 2006, 37 (01) :235-239
[9]
Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease [J].
Tayebjee, MH ;
Lip, GYH ;
Tan, KT ;
Patel, JV ;
Hughes, EA ;
MacFadyen, RJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (03) :339-345
[10]
Matrix metalloproteinases and atherosclerosis [J].
Watanabe N. ;
Ikeda U. .
Current Atherosclerosis Reports, 2004, 6 (2) :112-120